Global Controlled Release Drug Delivery Market Overview
Controlled Release Drug Delivery Market Size was valued at USD 20.5 Billion in 2022. The Controlled Release Drug Delivery market industry is projected to grow from USD 22.67 Billion in 2023 to USD 50.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.60% during the forecast period (2023 - 2032).The increasing frequency of chronic illnesses, along with the growing demand for controlled release medicine delivery are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Zydus Lifesciences announced that it had introduced Mirabegron extended-release tablets of 25 mg to the U.S. market in April 2024. The company will manufacture this drug to treat overactive bladder symptoms that show urgent urinary incontinence and increased rates of micturition at a group’s formulation manufacturing facility based in Ahmedabad, India. Zydus Lifesciences also noted that it had already obtained final approval from the United States Food and Drug Administration (USFDA) for marketing Mirabegron extended-release tablets USP 25 mg and 50 mg. The firm has claimed having launched the generic version of Mirabegron extended-release tablets, USP 25 mg, among the first suppliers in the United States market and is set to launch a version with strength of 50mg soon.
IFF, a global leader in the food & beverages industry as well as home and personal care products, announces its new controlled-release platform for its range of controlled-release products like METHOCEL™, ETHOCEL™, and POLYOX™. The “Timing is Everything” brand provides full pharmaceutical solutions regarding therapies to the advantage of patients, stressing on-time delivery guidelines on medicinal ingredients while enhancing patient compliance. It has educational resources for partners, including access to experts in different fields.
Eli Lilly and Company (NYSE: LLY) announced that Omvoh™ infusion (300 mg/15 mL)/injection (100 mg/mL), the first interleukin-23p19 (IL-23p19) antagonist approved by the FDA for moderately to severely active ulcerative colitis (U.C.) treatment in adults was approved by U.S Food and Drug Administration today October 2023. Omvoh is a significant breakthrough because it is currently the only U.C. treatment specifically tailored toward IL-23 p19, a cytokine responsible for inflammation related to ulcerative colitis. The support of the approval was based on data from the LUCENT program, which included two randomized, double-blind, placebo-controlled Phase 3 clinical trials: one twelve-week induction study (UC-1) and one forty-week maintenance study (UC-2) for continued treatment over fifty-two weeks.
Controlled Release Drug Delivery Market Trends
- Growing spending on R&D is driving the market growth
Market CAGR for controlled release drug delivery is being driven by the R&D. Constantly increasing R&D investment by pharmaceutical research companies concentrating on developing effective medicines for chronic and noncommunicable illnesses such as diabetes, cancer, and hypertension would most likely fuel market growth throughout the projection period. Taris, a biomedical R&D company, for example, has a controlled-release medication delivery system in their pipeline product TAR-200 (Gemcitabine), which is used to treat bladder cancer. Furthermore, Johnson & Johnson is scheduled to complete the acquisition of Taris Biomedical in 2020. One of the primary reasons for the purchase is its flagship investigational pharmaceutical, TAR-200.
The rising geriatric and pediatric population globally is driving market development, owing mostly to non-adherence to medication regimens, which is quite frequent among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which impacts their medication usage. Furthermore, their bodies cannot endure excessive dosages and strong adverse effects of medications. As a result, the need for controlled-release medication delivery systems is predicted to rise in tandem with the patient population. Controlled-release drug administration provides for considerable dose and dosage frequency reductions, the prevention of aberrant fluctuations in plasma drug levels, improved effectiveness, improved patient compliance, and the achievement of the consistent pharmacological impact of the supplied medication. Control releases drug delivery systems, instead of standard delivery methods, produce a longer therapeutic impact by releasing medicine to the target location at a predetermined time and with predictable drug release kinetics. As a result of the additional benefits provided by the controlled release delivery system. Thus, driving the Controlled Release Drug Delivery market revenue.
Controlled Release Drug Delivery Market Segment Insights
Controlled Release Drug Delivery Route of administration Insights
The Controlled Release Drug Delivery market segmentation, based on the route of administration, includes the Wurster technique, coacervation, microencapsulation, implants, transdermal, and targeted delivery. The targeted delivery segment dominated the market, accounting for 35% of market revenue. Targeted delivery permits drugs to be placed away from regions that might induce drug toxicity while providing the desired site of action. It is a popular drug delivery method because it increases bioavailability and localizes the medicine, improving absorption, reducing changes in circulating drug levels, and lowering the risk of adverse effects.
Controlled Release Drug Delivery Release Mechanism Insights
The Controlled Release Drug Delivery market segmentation, based on release mechanism, includes polymer-based systems, micro reservoir partition controlled drug delivery systems, feedback-regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated. The feedback-regulated drug delivery systems segment dominated the market. Due to their usefulness in treating ailments, including diabetes. Furthermore, increased R&D initiatives to capitalize on the potential of feedback-regulated controlled ways of medication administration as countermeasures will promote market expansion. Furthermore, increased R&D initiatives to utilize the potential of feedback-regulated, controlled drug delivery systems as antidotes are likely to boost market expansion.
Controlled Release Drug Delivery Application Insights
The Controlled Release Drug Delivery market segmentation, based on Application, includes metered dose inhalers, injectable, infusion pumps, oral controlled-drug delivery systems, transdermal and ocular patches, and drug-eluting stents. The oral controlled-drug delivery systems generated the most income. Owing to its regular usage and availability. Metered dosage inhalers are another profitable market predicted to increase rapidly during the projection period. The rising frequency of respiratory illnesses and regular product and technology breakthroughs are projected to boost category growth in the long run.
Figure 1: Controlled Release Drug Delivery Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Controlled Release Drug Delivery Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Controlled Release Drug Delivery market area will dominate this market; government measures to support the development of controlled-release medication delivery and increasing R&D spending are projected to drive market expansion in the area. Furthermore, the presence of important market participants encourages using controlled-release medication delivery methods. The rising prevalence of chronic illnesses such as cancer, diabetes, and heart ailments is boosting market growth.
Thus, the major countries studied in the market report are The US, Canada, German, Japan, India, France, the UK, Italy, Spain, China, Australia, South Korea, and Brazil.
Figure 2: CONTROLLED RELEASE DRUG DELIVERY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Controlled Release Drug Delivery because of the region's increased R&D efforts and large pharmaceutical businesses. Furthermore, the German Controlled Drug Delivery market dominated, while the UK Controlled Drug Delivery market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Controlled Release Drug Delivery Market will develop at the quickest CAGR. The region is getting international prominence as the pharmaceutical sector develops. Future growth of the market is predicted. Furthermore, China's Controlled Drug Delivery market had the highest market share, whereas India's Controlled Drug Delivery market was the Asia-Pacific region's fastest growing.
Controlled Release Drug Delivery Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Controlled Release Drug Delivery market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Controlled Release Drug Delivery industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Controlled Release Drug Delivery industry to serve clients and expand the market sector. The Controlled Release Drug Delivery industry has provided some of the most important benefits recently. Ripple Therapies., AstraZeneca plc, and other major companies in the Controlled Release Drug Delivery market are aiming to enhance market demand by investing in research and development activities.
Ripple Therapies is a clinical-stage business that enhances ocular therapies through controlled, long-term drug delivery. Their executive team has managed small and big public and private firms through various stages of growth and funding techniques. They successfully sold Interface Biologics' surface modification business to Evonik in 2019 and formed Ripple Therapeutics in January 2020. Ripple's initial product, IBE-814 IVT, is a proprietary intravitreal Dexamethasone prodrug implant with a 6-9 month duration that targets diabetic macular edoema (DME) and retinal vein occlusion (RVO). The FDA has approved a 505(b)2 pathway for IBE-814 IVT, and a Phase 2 study is now underway. In February 2023, Ripple Therapeutics, a prominent ophthalmic continuous drug delivery company, and Hovione, a spray drying and particle engineering pioneer, have forged a strategic partnership to expand the use of Ripple's Epidel platform beyond ocular applications.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology corporation headquartered in Cambridge, England. Its product portfolio includes treatments for important cancer, cardiology, gastrointestinal, infection, neurology, respiratory, and inflammation disorders. It was engaged in the development of the Oxford-AstraZeneca COVID-19 vaccine. They are a worldwide pharmaceutical firm driven by research and focuses on patients. They are committed to altering the future of healthcare by using the power of science to benefit individuals, society, and the world. Their company is structured to meet their goal of pushing the limits of science to provide life-changing medicines through their innovative approach.Their R&D and commercial operations encourage faster decision-making and the introduction of novel medications across all their therapeutic areas. In December 2021, AstraZeneca is working on the next generation of medicine delivery technologies. The company's scientists are focused on removing obstacles between the most promising new medicine candidates and their targets in tissues and cells. Finally, these next-generation drug delivery technologies promise to translate the scientific progress that has led to the company's groundbreaking new modalities into therapeutic advantages for patients.
Key Companies in the Controlled Release Drug Delivery market include
- Depomed, Inc. (US)
- Coating Place, Inc.(US)
- Corium International Inc.(US)
- Alza Corporation (Johnson & Johnson)(US)
- Pfizer Inc.(US)
- SKY Pharmaceuticals Pvt. Ltd.(China)
- AstraZeneca (US)
- Biogen (US)
- GlaxoSmithKline (UK)
- Novartis (UK)
- Allergan (Ireland)
- Collegium Pharmaceutical (US).
Controlled Release Drug Delivery Industry Developments
March 2022:EUDRATEC SoluFlow is a novel microparticle technology developed by Evonik to improve the solubility of active medicinal components in oral medication formulations. Because more than 70% of novel small compounds are insoluble, EUDRATEC SoluFlow facilitates the discovery of new oral therapies across various disorders, including cancer, cardiovascular disease, infectious disease, and diabetes.
March 2022:Coloron introduced OptiClenz, a high-capacity, targeted, and repeatable cleaning system for tablet coating equipment.
Controlled Release Drug Delivery Market Segmentation
Controlled Release Drug Delivery Route Of Administration Outlook
-
Wurster Technique
-
Coacervation
-
Micro Encapsulation
-
Implants
-
Transdermal
-
Targeted Delivery
Controlled Release Drug Delivery Release Mechanism Outlook
-
Polymer Based Systems
-
Micro Reservoir Partition Controlled Drug Delivery Systems
-
Feedback Regulated Drug Delivery Systems
-
Activation-modulated Drug Delivery Systems
-
Chemically Activated
Controlled Release Drug Delivery Application Outlook
Controlled Release Drug Delivery Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 20.5 Billion |
| Market Size 2023 |
USD 22.67 Billion |
| Market Size 2032 |
USD 50.67 Billion |
| Compound Annual Growth Rate (CAGR) |
10.60% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Route of administration, Release Mechanism, Application, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Depomed, Inc. (US), Coating Place, Inc.(US), Corium International Inc.(US), Alza Corporation (Johnson & Johnson)(US), Pfizer Inc.(US), SKY Pharmaceuticals Pvt. Ltd.(China), AstraZeneca (US),Biogen (US), GlaxoSmithKline (UK), Novartis (UK), Allergan (‎Ireland), Collegium Pharmaceutical (US) |
| Key Market Opportunities |
Obesity in children, healthier and more balanced diets |
| Key Market Dynamics |
Increase in health difficulties and worries, leading in costly operations |
Controlled Release Drug Delivery Market Highlights:
Frequently Asked Questions (FAQ) :
The Controlled Release Drug Delivery market size was valued at USD 20.5 Billion in 2022.
The market is projected to grow at a CAGR of 10.60% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Depomed, Inc. (US), Coating Place, Inc.(US), Corium International Inc.(US), Alza Corporation (Johnson & Johnson)(US),.
The Targeted Delivery dominated the market in 2022.
The Oral Controlled-drug delivery Systems had the largest share in the market.
